The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli
Open accessAbstract
During the last decade, the efforts to combat multidrug-resistant (MDR) microorganisms mainly focused on gram-positive bacteria, namely, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. While a large number of hospitals have implemented more rigorous infection
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,618
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,431
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Resistance in Gram-Negative Bacteria: Enterobacteriaceae
Paterson, D. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.013 · Cited by 874
Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community
Pitout, J. D. D., Nordmann, P., Laupland, K. B., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki166 · Cited by 790 · cited 1×
“Also, the recently described dissemination of ESBL-producing Enterobacteriaceae in the community poses a new threat, since this may become a powerful reservoir for the continued influx of resistant strains into hospitals (3, 60).”
BackgroundLautenbach, E., Patel, J. B., Bilker, W. B., Edelstein, P. H., & Fishman, N. O. (2001) · Clinical Infectious Diseases · doi:10.1086/319757 · Cited by 747
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabo, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 741
Schwaber, M. J., & Carmeli, Y. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm318 · Cited by 626
Self-citationMultidrug-Resistant Pseudomonas aeruginosa : Risk Factors and Clinical Impact
Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S., & Carmeli, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.43-48.2006 · Cited by 617
Self-citationThe β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter
Livermore, D. M., & Woodford, N. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.07.008 · Cited by 510
Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E. M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01509-06 · Cited by 461
Schwaber, M. J., Navon-Venezia, S., Kaye, K. S., Ben-Ami, R., Schwartz, D., & Carmeli, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1257-1262.2006 · Cited by 416
Self-citationHusain, S., Munoz, P., Forrest, G., Alexander, B. D., Somani, J., Brennan, K., Wagener, M. M., & Singh, N. (2005) · Clinical Infectious Diseases · doi:10.1086/426445 · Cited by 401
Falagas, M. E., Koletsi, P. K., & Bliziotis, I. A. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46747-0 · Cited by 399
Karlowsky, J. A., Draghi, D. C., Jones, M. E., Thornsberry, C., Friedland, I. R., & Sahm, D. F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1681-1688.2003 · Cited by 351
Influx of Extended-Spectrum -Lactamase--Producing Enterobacteriaceae into the Hospital
Ben-Ami, R., Schwaber, M. J., Navon-Venezia, S., Schwartz, D., Giladi, M., Chmelnitsky, I., Leavitt, A., & Carmeli, Y. (2006) · Clinical Infectious Diseases · doi:10.1086/500936 · Cited by 317
Self-citationGales, A. C., Jones, R. N., Turnidge, J., Rennie, R., & Ramphal, R. (2001) · Clinical Infectious Diseases · doi:10.1086/320186 · Cited by 309
Gales, A. C., Jones, R. N., & Sader, H. S. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01351.x · Cited by 302
The importance of the development of antibiotic resistance in Staphylococcus aureus
Schito, G. C. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01343.x · Cited by 302
Melzer, M., & Petersen, I. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.04.007 · Cited by 298
Tumbarello, M., Spanu, T., Sanguinetti, M., Citton, R., Montuori, E., Leone, F., Fadda, G., & Cauda, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.498-504.2006 · Cited by 283
Tigecycline: what is it, and where should it be used?
Livermore, D. M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki291 · Cited by 261
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii
Peleg, A. Y., Adams, J., & Paterson, D. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-06 · Cited by 257
Leavitt, A., Navon-Venezia, S., Chmelnitsky, I., Schwaber, M. J., & Carmeli, Y. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00299-07 · Cited by 256
Self-citationPlayford, E. G., Craig, J. C., & Iredell, J. R. (2007) · Journal of Hospital Infection · doi:10.1016/j.jhin.2006.11.010 · Cited by 251
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Peleg, A. Y., Potoski, B. A., Rea, R., Adams, J., Sethi, J., Capitano, B., Husain, S., Kwak, E. J., Bhat, S. V., & Paterson, D. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl441 · Cited by 248
Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting
Navon-Venezia, S., Ben-Ami, R., & Carmeli, Y. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000171920.44809.f0 · Cited by 242
Self-citationVirginia Villegas, M., Lolans, K., Correa, A., Jose Suarez, C., Lopez, J. A., Vallejo, M., & Quinn, J. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00186-06 · Cited by 232
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria
Falagas, M. E., Bliziotis, I. A., Kasiakou, S. K., Samonis, G., Athanassopoulou, P., & Michalopoulos, A. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-24 · Cited by 224
The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril!
Thomson, J. M., & Bonomo, R. A. (2005) · Current Opinion in Microbiology · doi:10.1016/j.mib.2005.08.014 · Cited by 212
Fluoroquinolone-Resistant Pseudomonas aeruginosa: Assessment of Risk Factors and Clinical Impact
Gasink, L. B., Fishman, N. O., Weiner, M. G., Nachamkin, I., Bilker, W. B., & Lautenbach, E. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.029 · Cited by 206
Ruzin, A., Visalli, M. A., Keeney, D., & Bradford, P. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1017-1022.2005 · Cited by 203
Landman, D., Bratu, S., Kochar, S., Panwar, M., Trehan, M., Doymaz, M., & Quale, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm129 · Cited by 192
OXA β-lactamases in Acinetobacter: the story so far
Brown, S., & Amyes, S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki425 · Cited by 189
Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia
Kwon, K. T., Oh, W. S., Song, J.-H., Chang, H.-H., Jung, S.-I., Kim, S.-W., Ryu, S. Y., Heo, S. T., Jung, D. S., Rhee, J.-Y., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl499 · Cited by 188
Rossi, F. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl199 · Cited by 181
Morosini, M.-I., García-Castillo, M., Coque, T. M., Valverde, A., Novais, A., Loza, E., Baquero, F., & Cantón, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00155-06 · Cited by 166
Kaye, K. S., Harris, A. D., Samore, M. H., & Carmeli, Y. (2005) · Infection Control and Hospital Epidemiology · doi:10.1086/502550 · Cited by 163
Self-citationNavon-Venezia, S., Chmelnitsky, I., Leavitt, A., Schwaber, M. J., Schwartz, D., & Carmeli, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00438-06 · Cited by 160
Self-citationSchwaber, M. J., Navon-Venezia, S., Schwartz, D., & Carmeli, Y. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.2137-2139.2005 · Cited by 160
Self-citationZaoutis, T. E., Goyal, M., Chu, J. H., Coffin, S. E., Bell, L. M., Nachamkin, I., McGowan, K. L., Bilker, W. B., & Lautenbach, E. (2005) · PEDIATRICS · doi:10.1542/peds.2004-1289 · Cited by 154
Hirakata, Y., Matsuda, J., Miyazaki, Y., Kamihira, S., Kawakami, S., Miyazawa, Y., Ono, Y., Nakazaki, N., Hirata, Y., Inoue, M., et al. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.04.004 · Cited by 154
Cao, B., Wang, H., Sun, H., Zhu, Y., & Chen, M. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.03.021 · Cited by 143
Lee, S. Y., Kotapati, S., Kuti, J. L., Nightingale, C. H., & Nicolau, D. P. (2006) · Infection Control and Hospital Epidemiology · doi:10.1086/507962 · Cited by 143
Bouchillon, S. K., Johnson, B., Hoban, D., Johnson, J. L., Dowzicky, M. J., Wu, D., Visalli, M. A., & Bradford, P. A. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.01.010 · Cited by 141
A Step Closer to Extreme Drug Resistance (XDR) in Gram-Negative Bacilli
Paterson, D. L., & Doi, Y. (2007) · Clinical Infectious Diseases · doi:10.1086/522287 · Cited by 139
Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection
Defez, C., Fabbro-Péray, P., Bouziges, N., Gouby, A., Mahamat, A., Daurès, J., & Sotto, A. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.03.022 · Cited by 132
Effects of Efflux Transporter Genes on Susceptibility of Escherichia coli to Tigecycline (GAR-936)
Hirata, T., Saito, A., Nishino, K., Tamura, N., & Yamaguchi, A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2179-2184.2004 · Cited by 124
Treatment of multidrug resistant Acinetobacter
Murray, C. K., & Hospenthal, D. R. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000185985.64759.41 · Cited by 103
Anderson, D. J., Engemann, J. J., Harrell, L. J., Carmeli, Y., Reller, L. B., & Kaye, K. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1715-1720.2006 · Cited by 102
Self-citationGoossens, H. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00690.x · Cited by 96
The Brooklyn Antibiotic Resistance Task Force (2002) · Infection Control and Hospital Epidemiology · doi:10.1086/502018 · Cited by 90
Tigecycline: A Novel Glycylcycline
Rubinstein, E., & Vaughan, D. (2005) · Drugs · doi:10.2165/00003495-200565100-00002 · Cited by 76
Endemic Multidrug-Resistant Pseudomonas aeruginosa in Critically Ill Patients
Ortega, B., Groeneveld, A. B. J., & Schultsz, C. (2004) · Infection Control · doi:10.1086/502303 · Cited by 76
Bhavnani, S. M., Ambrose, P. G., Craig, W. A., Dudley, M. N., & Jones, R. N. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.09.011 · Cited by 68
Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997–2002
重敏, 森., Weinberger, M., Siegman-Igra, Y., Lazarovitch, T., Ostfeld, I., Boldur, I., Samra, Z., Shula, H., Carmeli, Y., Rubinovitch, B., et al. (2005) · Journal of Hospital Infection · doi:10.1016/j.jhin.2005.01.007 · Cited by 67
Self-citationDantas, S. R. P. E., & Moretti-Branchini, M. L. (2003) · Infection Control and Hospital Epidemiology · doi:10.1086/502210 · Cited by 17
Cited by
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance
Navon-Venezia, S., Kondratyeva, K., & Carattoli, A. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux013 · Cited by 1,286
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Hospital Epidemiology and Infection Control in Acute-Care Settings
Sydnor, E. R. M., & Perl, T. M. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00027-10 · Cited by 652
“ESBLs inactivate broad-spectrum cephalosporins and beta-lactamases, and they are associated with beta-lactam resistance and frequent resistance to fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole (112, 231).”
BackgroundKlebsiella pneumoniae: an increasing threat to public health
Effah, C. Y., Sun, T., Liu, S., & Wu, Y. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-019-0343-8 · Cited by 558
Metadata
- Authors
- Giske, C. G., Monnet, D. L., Cars, O., & Carmeli, Y.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-03
- Volume
- 52
- Issue
- 3
- Pages
- 813-821
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2103517471
- Cited by
- 610
- References
- 61
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.